ALX Oncology (ALXO) said Friday that data from its ongoing phase 1/2 trial of its evorpacept investigational drug in combination with rituximab and lenalidomide in patients with indolent and aggressive relapsed or refractory B-cell non-Hodgkin lymphoma showed anti-tumor activity.
A median follow-up of 28 months on the patients revealed that the two-year progression-free survival rate was 69% and the two-year overall survival rate was 84%, while 80% achieved complete responses, the company said.
The complete response rate was higher than that of patients who received the standard-of-care rituximab and lenalidomide treatment, the company said.
The phase 2 portion of the study in patients with previously untreated indolent non-Hodgkin lymphoma is ongoing and has completed enrollment, the company added.
Shares of the company were down 9.3% in recent Friday trading.
Price: 0.55, Change: -0.06, Percent Change: -9.32
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.